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Structured abstract 
 
Purpose of review:  
Adolescents living with HIV (ALHIV) are the only age group with increasing HIV mortality at a time of 
global scale-up of access to antiretroviral therapy (ART). As a “treat all” strategy is implemented world 
wide, it is critically important to optimize retention and adherence for this vulnerable group. 
 
Recent findings:  
Adolescents and young adults living with HIV (AYALHIV) have poorer outcomes when compared to 
adults at each stage of the HIV care cascade, irrespective of income setting. Rates of viral 
suppression are lowest for ALHIV, and adherence to ART remains an enormous challenge. High 
quality studies of interventions to improve linkage to, and retention in, care on suppressive ART are 
starkly lacking for AYALHIV across the globe. However, examples of good practice are beginning to 
emerge but require large scale implementation studies with outcome data disaggregated by age, 
route of infection, and income setting, and include young pregnant women and key populations 
groups. 
 
Summary: 
There is an urgent need for evidence-based interventions addressing gaps in the adolescent HIV care 
cascade, including supporting retention in care and adherence to ART. 
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INTRODUCTION 
There are an estimated 1.8 million ALHIV globally, 80% living in sub-Saharan Africa [1]. In recent 
years, older adolescents (15-19 years) are the only age group with increasing HIV mortality, at a time 
of massive scale-up of treatment programs, and when mortality is declining in all other age groups 
[2,3**]. High adolescent HIV mortality reflects critical gaps in the HIV care cascade, including low 
rates of retention in care, and complex challenges with adherence to ART [4-15]. The adolescent 
years (10-19 years) encompass significant physiological and psychosocial changes that confer 
particular vulnerability for adolescents living with either perinatally (PHIV) or behaviorally acquired 
HIV infection (BHIV) [4,5,16-18]. These changes continue to impact outcomes into young adulthood 
(20-24 years) [7,10,18-20]. 
Failure to optimally diagnose, retain and treat adolescents and young adults living with HIV 
(AYALHIV) has broad implications for the global epidemic. Viral suppression is critical to preventing 
onward transmission and reducing morbidity and mortality [21-24]. The UNAIDS “90-90-90” goal that 
90% of persons living with HIV are diagnosed, 90% on treatment, and 90% virally suppressed in 
order to end the AIDS epidemic, cannot be achieved without a sustained and targeted effort to 
improve AYA outcomes [25,26]. We review recent research in AYALHIV retention in care and 
adherence to ART, from high and low or middle income countries (HIC and LMIC). 
 
AYA HIV CARE IN HIGH INCOME COUNTRIES 
90-90-90 targets are yet to be met for adults in many HIC and remain an enormous challenge for 
AYALHIV [27]. The rise in HIV-associated mortality in adolescence is driven by the emerging cohort 
of long-term survivors of the PHIV epidemic who join the ever-increasing numbers of BHIV AYA, 
although robust data interpretation is frequently hampered by lack of disaggregation by both age and 
route of infection [3**]. Further complexity for data collection occurs during transition, with tracking of 
ALHIV into adult care by accurate linkage of national pediatric and adult surveillance systems proving 
challenging [28*]. 
Reported adult retention and suppression rates vary widely for the HIV care continuum in HIC. 
Encouragingly, in 2016 all 90-90-90 targets were met for the first time in London, where 97% of those 
diagnosed received ART, with 97% suppressed <200c/ml [29**]. However, when disaggregated by 
age, disparities persist, with 89% of 15-24 year olds receiving treatment compared to 98% over 50 
years. Disaggregation by route of infection reveals lowest rates of suppression in PHIV (88%) [29**]. 
In the US, an estimated 51% of the 60,900 AYALHIV in 2013 remained undiagnosed, the highest rate 
in any age group [30]. Of those diagnosed in 2014, 68% were linked to care within one month, the 
lowest of any age group, 55% were retained in care, and 44% were suppressed [30]. Recent 
improvements are reported, at least for youth attending specialist services with adherence 
counselling, case management and integrated mental health and substance use services [31**]. Of 
467 BHIV youth, median age 23 years, linked to care for at least 1 year, 86% remained engaged, 
98% were prescribed ART, 89% achieved viral suppression, sustained in 59% [31**]. Taking the initial 
467 linked to care, 45% remained in care on sustained suppressive ART; leaving considerable scope 
for improvement. 
Looking at factors associated with retention, Hussen et al examined the care continuum for 72 
AYALHIV referred to adult services between 2004-2014 [32**]. Almost all attended once, but only 
56% were retained in care by year two. Viral suppression in pediatric care and shorter time between 
last pediatric and first adult appointment were associated with retention on suppressive ART in adult 
services [32**]. While transfer between pediatric and adult services has been highlighted as a 
particular barrier to retention, half of this cohort had disengaged from pediatric care prior to re-
enrolling in adult care, highlighting the complexity of disentangling the impact of service change from 
the multiple physical, psychosocial and economic challenges during adolescence [33]. Linked data for 
271 PHIV British youth tracked from pediatric to adult care showed a decline in CD4 counts prior to 
transfer; after transfer, counts continued to decline in black males, remained constant in white males 
and black females, and increased in white females [34*]. Age at transfer and moving hospital had no 
apparent impact, however more recent calendar year was associated with better outcomes, 
potentially reflecting improvements in ART and/or transition over time. Transition typically occurs 
during late adolescence in Europe, often extending into young adulthood in the US [33]. Populations 
vary by route of transmission; with predominantly PHIV in Europe and a larger proportion of BHIV in 
US cohorts. Comparison of transition outcomes by route of infection reviewed by Lam et al highlights 
the barriers faced, including the higher rates of accumulation of HIV-1 associated drug resistance 
mutations in PHIV compared to BHIV, resulting in more complex ART, impacting on adherence 
[35,36].The paucity of data on acquired drug resistance in ALHIV is highlighted. In the UK, 291 of 644 
adolescents transferring to adult care had resistance data available; 82% with resistance to ≥1 drug 
class, 56% to ≥2 classes and 12% triple-class resistance, reflecting the long-term consequence of 
poor paediatric viral suppression rates due to more limited ART options, unpalatable formulations, 
and dependency on parents/carers [37]. Small European cohorts have recently published post-
transition data for predominantly PHIV youth. In Holland, virological failure increased post-transition 
[38]. In contrast, a very small Swedish cohort (n=23) reported post-transition viral suppression rates 
above 90%, comparable to adults [39]. However, HIC mortality data is emerging; 117 HIV-related 
deaths were reported in 60,900 American 15-24 year-olds [3,30]. An mortality audit of young UK 
adults with PHIV highlights the interplay of mental health diagnoses with poor adherence, leading to 
advanced disease [40]. 
How do we improve retention in care and adherence to ART? Fortenberry et al show how 
addressing the need for structural change in fragmented US services improves outcomes for 
AYALHIV [41**]. Through a coordinated program of cross-agency collaboration, youth-friendly linkage 
to care and community mobilization, more than 75% of almost 4000 youth linked to care, with nearly 
90% retained [41**]. A US single center pilot intervention comparing a program of non-traditional HIV 
testing, motivational interviewing, and case management with standard of care for newly diagnosed 
youth (18-24 years) showed significantly higher rates of linkage to care (96% vs. 57%, P < 0.001) 
within a shorter time frame and improved adherence for the intervention group [42]. Strategies to 
improve re-engagement after loss to follow-up (LTFU) from adult care through outreach coordinators, 
peer facilitators, and LTFU protocols have encouraging results but lack age-disaggregated data for 
AYA [43,44]. The use of mobile phone technology to improve adherence in adolescents has shown 
promise in terms of feasibility and acceptability, although more modest efficacy, and is being 
evaluated further in the US “weCare” program [45-47]. This US-based program targets MSM, ages 
13-34 years, who are consumers of social media using Facebook, text messaging, and established 
GPS-based mobile applications as a platform for improving linkage and retention to care [47].  
Outcome data is awaited for this group with typically very low retention rates. The unmet needs and 
lack of outcome data for young people in key population groups, including pregnant adolescents, 
those who inject drugs, transgender youth, sex workers, and AYA within the criminal justice system, 
requires urgent attention.  
 
AYA HIV CARE IN LOW AND MIDDLE INCOME COUNTRIES 
HIV poses a significant threat to adolescents in sub-Saharan Africa (SSA) today and an important 
cause of adolescent mortality in this region, with an estimated 36,000 deaths per year [2,16]. From 
2000 to 2015, adolescent AIDS-related deaths more than doubled in the 25 countries with 86% of the 
world’s ALHIV [48]. Compared to their pediatric and adult counterparts in LMIC – as in HIC – 
AYALHIV have poorer retention in care, lower rates of virological suppression, and higher mortality 
[3**,49,50].  
Adolescent disengagement from care presents a major challenge for global HIV programs. 
Only 20% of the world’s ALHIV are on ART [48]. In South Africa, youth (15-24 years) have the lowest 
proportion on ART of any age group, with only an estimated 10% virally suppressed [51,52*]. In 
pooled data from global IeDEA cohorts including 115,549 children (0-19 years) enrolled in HIV care, 
20.8% were LTFU before ART initiation, and adolescents had the lowest initiation rate (54.3%) [53]. 
In an analysis of East Africa IeDEA sites, older adolescents (15-19 years) experienced the highest 
rate of LTFU within 2 years (51%) and the lowest ART initiation rate (20%) [54]. Risk for LTFU was 
increased for adolescents not eligible for ART prior to implementation of the treat-all strategy [55**]. 
There is additional concern for LTFU during the transition from pediatric to adult services 
[28*,35,56,57]. 
While there is limited qualitative data focused on adolescent retention, available studies from 
sub-Saharan Africa illustrate emerging challenges faced by adolescents accessing HIV care in this 
setting (Table 1) [58**-64]. Predominant barriers include perceived and enacted stigma, fear of 
disclosure of HIV status to the adolescent or others [58**-62], and mental health issues 
[5,60,65**,66*]. These are particularly complex for PHIV adolescents, who may experience uniquely 
challenging circumstances, including illness or death of family members; severe, life-threatening 
illness with delayed diagnosis; the difficult experience of learning their HIV status; and social isolation 
[5,60,66*-70]. Poverty, food insecurity, and family factors are also dominant [60,61,63,71], in addition 
to elements of the clinic [59,61] and school environments [59,61]. Emerging facilitators include strong 
social support networks, supported disclosure of HIV status to the child or close family members, 
family stability and support, and future orientation and self-sufficiency of adolescents [58**,60-62,64]. 
Efforts to improve retention of AYALHIV will need to mitigate the significant challenges that pervade 
adolescent engagement in care, for example by supporting disclosure of HIV status to the adolescent, 
reducing stigma in the community, school and clinic settings, and facilitating access to mental health 
support [59,60,62,64,66*,68]. 
Few studies have evaluated interventions to improve AYALHIV retention in LMIC, including the 
impact of adolescent-friendly services (AFS) [72-74]. In Kenya, AFS were implemented at six clinics; 
training providers in adolescent care, monthly dedicated adolescent HIV clinics, integrating sexual 
and reproductive health, and establishing peer support programs [75]. Pre-ART LTFU decreased at 
AFS clinics, although not statistically significant, with no difference in LTFU or mortality between AFS 
and non-AFS clinics, and no impact on post-ART LTFU [75]. Another study in Kenya evaluated 
factors associated with LTFU in a cohort of 15-21 year-olds enrolled at a youth-dedicated clinic and a 
family oriented clinic. While there was a high proportion LTFU (57%), with 26% LTFU immediately, 
enrollment in a youth-specific clinic was not associated with reduced LTFU [76].   
By contrast, implementation of an adolescent-friendly clinic in Haiti was associated with 
improvements in the proportion of adolescents ages 13-19 enrolling in care, being assessed for ART 
eligibility, initiating ART, and a reduction in pre-ART attrition from 61% to 50% [9]. There was no 
impact, however, on long-term retention. In Kenya, implementation of AFS providing peer navigators, 
peer counselling, and psychosocial support at clinics and schools demonstrated substantial 
improvement in retention of AYALHIV ages 15-21 [77]. A large multi-country study evaluated factors 
associated with LTFU of AYALHIV ages 15-24, including availability of specific AFS [8]. Pre-ART 
LTFU was not associated with any of the evaluated AFS. Post-ART LTFU was lower at clinics 
providing condoms, or offering adolescent support groups. In Rwanda, where there was 
heterogeneity in the availability of adolescent peer educators, there was lower post-ART LTFU, 
though this was not significant due to small clinic size. 
While there are considerable limitations to the current literature, evidence from observational 
studies of the impact of AFS on retention is mixed [8,9,54,72,73**,75,76,78,79]. It is possible that 
provision of AFS may be insufficient to mitigate the causes of LTFU for many AYALHIV. In some 
contexts, there may be high initial attrition from HIV care prior to engagement with AFS 
[8,53,54,76,80,81]. Furthermore, stigma, psychosocial issues, family and community factors may be 
central to disengagement, and must be mitigated to realize optimal adolescent HIV outcomes 
[9,58,59,75]. In adult studies, community-support models have shown promise in addressing stigma 
and other social factors while facilitating care [73**,82]. An ongoing cluster randomized controlled trial 
in Zimbabwe will evaluate the impact of a multifaceted community-based program to improve ALHIV 
retention and adherence [83]. 
Studies of interventions to improve adolescent retention in care are needed from multiple 
approaches [72], particularly for pregnant adolescents and adolescents from key populations (Table 
2) [84**-87]. To be most be impactful and relevant to youth, this research should evaluate adolescent 
needs in local contexts, undertaken through collaborative partnerships with AYALHIV themselves 
[61,88]. 
Sustaining ART adherence is critical to achieve virological suppression, prevent drug 
resistance, halt disease progression, and prevent transmission [48,49,89]. Evidence suggests that 
AYALHIV fail to achieve and maintain adequate adherence. In a study from South Africa, only 27% of 
9-19 year-olds achieved viral suppression, compared to 63% of 20-29 year-olds [89]. In addition, 
adolescents had an increased risk of virological failure (AHR=2.06, p=.002) [89]. While systematic 
reviews have suggested that children, adolescents and adults in LMIC have higher rates of ART 
adherence than those in HIC [90-92], adherence is typically measured in LMIC by self- or caregiver-
reports, which likely do not capture the full extent of non-adherence [92,93]. Implementing other 
adherence measures for AYALHIV, including viral load, electronic dose and therapeutic drug 
monitoring, hair drug concentrations, and novel approaches to pill counts such as looking for 
“overadherence”, all reveal the non-adherence and challenges such as treatment interruptions that 
compromise viral suppression [94-98]. 
 The evidence for interventions to improve AYA adherence in LMIC remains extremely sparse 
[99]. A recent systematic review found only two effective interventions among high-quality studies: a 
phone-based counseling approach with adherence monitors and weekly individual and family 
counseling [99]. Only one of these studies was done in a LMIC (Thailand) [100]. Patient-oriented 
adaptations of healthcare delivery systems are considered a key requirement to improve ART 
adherence and retention in care for adults, as they can overcome structural barriers; allow more time 
and resources for adherence, disclosure, or mental health support; and lessen treatment fatigue and 
LTFU [101]. Evaluations of how such adaptations might improve AYALHIV outcomes are lacking. 
Another potential strategy for improving AYA adherence may come in the form of ART options with a 
higher genetic barrier to resistance and in once daily fixed dose combinations. Integrase inhibitors 
such as dolutegravir [102] have been effective in achieving high rates of viral suppression in other 
populations and long-acting injectable ART remains an attractive future goal. Access to newer ART 
classes is particularly pertinent given the extremely worryingly levels of transmitted drug resistance to 
both NNRTIs and NRTIs emerging in infants from sub Saharan Africa for whom treatment options 
currently are extremely limited [103**]. 
 
CONCLUSION 
AYALHIV are an acutely vulnerable group, with worse outcomes than adults at each stage of the care 
cascade, in all global settings. There is an urgent need to develop an evidence base for interventions 
to improve adolescent retention and adherence to ART. As a “treat all” strategy is implemented 
globally, there is a need to identify interventions that are cost-effective, scalable, and sustainable, to 
ensure adolescent retention in care and adherence to ART, to halt the rise in adolescent HIV 
associated mortality, and ultimately to bring an end to the HIV/AIDS epidemic. 
 
KEY POINTS  
• Adolescence is the only age group where HIV associated mortality continues to rise 
• AYALHIV experience poorer rates of retention in care and adherence to ART compared to 
adults, due to multiple psychosocial challenges that complicate HIV care at this developmental 
stage. 
• There are remarkably few studies of targeted interventions to improve retention in care and 
adherence to ART or AYALHIV.  
• There is a need for data, disaggregated by age and route of infection on outcomes and 
targeted interventions for retention in HIV care of for AYALHIV that includes pregnant 
adolescents, and those from key populations groups, both in HIC and LMIC. 
• Interventions are needed which mitigate stigma and strengthen social support for AYALHIV to 
improve retention in care. 
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Table 1. Qualitative studies which include evaluation of factors underlying adolescent retention in LMIC. 
 
Study Country Populations Area of study Barriers Facilitators 
Wolf [59] Kenya LTFU AYALHIV 15-
21 years; 
Community health 
workers who work 
with LTFU 
AYALHIV; 
Educators from 
schools attended by 
LTFU AYALHIV 
Reasons for LTFU among 
AYALHIV 
Stigma and fear of disclosure 
within the home/family, school, 
and clinic, and resulting impact 
on dependent relationships 
between AYALHIV and adults in 
these settings. 
Not specifically 
studied. 
Petersen 
[60]  
South 
Africa 
ALHIV 14-16 years; 
Caregivers of 
ALHIV 
Psychosocial challenges 
and protective influences for 
coping in ALHIV 
Death of biological parents; 
coming to terms with HIV 
infection; external stigma and 
discrimination; disclosure 
challenges; lack of financial, 
family, or social support. 
ART; HIV education; 
future orientation; 
social support; 
financial support. 
Busza 
[61] 
Zimbabwe Caregivers of 
children ages 6-15 
engaged in care; 
Key informants 
from community 
organizations 
providing 
adherence support 
Factors influencing linkage 
and retention to inform 
design of a community-
based intervention to 
increase retention of 
children living with HIV 
Distance to clinic; transportation 
cost; fear of HIV status 
disclosure to the child or others; 
unstable family structure; drug 
stock-outs; HCW absenteeism; 
unsympathetic school 
environments. 
Family openness; 
availability of 
practical assistance 
and psychosocial 
support from 
community members. 
Mburu 
[62] 
Zambia ALHIV 10-19 years; 
Healthcare 
providers of ALHIV; 
Caregivers of 
ALHIV 
ALHIV experiences within a 
socioecological model 
Internalized stigma; external 
stigma and discrimination in 
schools; inflexible clinic hours, 
staff shortages; lack of policies 
addressing ALHIV. 
Resilience; family 
and peer support; 
livelihood, nutritional 
support; 
psychological 
support 
Luseno 
[63] 
Kenya ALHIV 15-19 years, 
in care, out of care, 
or never enrolled; 
Caregivers of 
ALHIV 
ALHIV experiences with HIV 
services along the care 
cascade 
ART side effects; pill burden; 
limited access to clean water and 
nutrition 
Supportive 
environments in 
family, school, health 
facility 
Midtbø Botswana ALHIV;  Relationship between External stigma HIV status disclosure 
[64] and 
Tanzania 
Healthcare workers disclosure, ART, and ALHIV 
psychosocial wellbeing 
to ALHIV; peer 
support groups 
Abbreviations: ALHIV, adolescents living with HIV; ART, antiretroviral therapy; AYALHIV, adolescents and young adults living with HIV; 
HCW, healthcare worker; HIV, human immunodeficiency virus; LTFU, lost to follow-up. 
Table 2. Areas of intervention for adolescent retention, for which research is needed. 
 
Area of Intervention to be Studied Examples 
Evaluation or adaptation of evidence-based interventions from 
adult HIV literature 
Home-based care 
Task shifting 
Broad interventions to make HIV care more responsive to the 
needs of adolescents 
Adolescent-friendly services 
Peer counseling 
Peer support groups 
Disclosure support 
Targeted interventions to improve retention for adolescents at 
high risk of disengagement 
Adolescent and family 
counselling 
Financial interventions 
Intensified follow-up from 
community health workers 
Interventions for pregnant adolescents  
Interventions for adolescents from key populations  
Abbreviations: HIV, human immunodeficiency virus. 
